This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the potential of ImmunityBio’s combination immunotherapy, Nant Cancer Vaccine in pancreatic cancer
Ticker(s): IBRXWho's the expert?
Institution: UCSF
- Professor of Medicine (Hematology/Oncology) and specialist in colorectal and gastrointestinal cancer, with a particular interest in pancreatic cancer.
- Treats 40-50 patients with Advanced Pancreatic Cancer.
- Heads the GI site committee regarding development and oversight of trials focused on pancreatic, colorectal, hepatobiliary, esophagogastric, and neuroendocrine malignancies; and also chairs the Cancer Center scientific Protocol Review Committee.
Interview GoalThis conversation will focus on the potential for success of the NANT Cancer vaccine from IBRX.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
